Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both

Has Novartis’ T-Charge been overtaken by in vivo CAR-Ts? Execs argue there’s room for both

  • May 22, 2026

It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therapies.

Leave A Comment

Fields (*) Mark are Required